AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion

AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company has also submitted upadacitinib (RINVOQ) for FDA and EMA review as a ...

MedImpact Offers Humira Biosimilar 95% Below the Cost of Humira to Any Hospital or Pharmacy

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...
Fierce Pharma

AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
STAT

The health care economy, and a surprising Humira chart

President Trump blared about the “GREAT JOBS NUMBERS” from last week’s jobs report. But a deeper look at the data shows the U ...
Zacks Investment Research on MSN

AbbVie down since Q4 earnings report: How to play the stock

AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4.
Forbes

Coherus BioSciences And Mark Cuban’s Drug Company Aim To Disrupt Humira-Referenced Biosimilar Space With Launch Of Yusimry At A 85% Discount

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
Yahoo

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

1 No-Brainer Dividend Stock to Buy on the Dip

The recent dip may have been an overreaction.
Investor's Business Daily on MSN

AbbVie pummeled after delivering a fourth-quarter beat — on the back of Humira

Investors pummeled AbbVie stock Wednesday after the company delivered a fourth-quarter sales beat, thanks to Humira.
MarketWatch

For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say

AbbVie’s ABBV rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical ...
MedPage Today

Humira Clobbers Biosimilars in Battle for Part D Coverage

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
Yahoo

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...